Prime Medicine (PRME) Earnings Date & Reports

Key Takeaways

• Prime Medicine is expected to report third-quarter 2026 results in early November, with Wall Street consensus modeling a net loss of roughly $0.23 per share.
• The company remains pre-commercial, so reported revenue is minimal collaboration income, and investors will focus on cash position, research and development spending, and pipeline updates.
• Recent progress — including the first patient dosed in the Phase 1/2 trial of PM577a for Wilson disease — raises the stakes for commentary on execution and enrollment.
• Historical results show an inconsistent beat record, with recent quarters landing in line, above, and below consensus, underscoring the stock's sensitivity to small EPS and revenue variances.
• Cash runway is a central theme, with the company's last disclosed balance of $149.2 million in cash and investments expected to fund operations into 2027.
• For more context, you can review Prime Medicine's Major News and Today's Price Move, along with Price Targets and a detailed Forecast on Tickeron's dedicated pages.
• Investors seeking automated market insights may also want to explore Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

Prime Medicine (PRME) is a clinical-stage biotechnology company developing one-time genetic therapies using its proprietary Prime Editing platform. Because the company is pre-commercial, its quarterly report is less about top-line growth and more about clinical execution, spending discipline, and balance-sheet durability. Investors will be watching whether management reiterates its cash runway guidance into 2027, how research and development (R&D) costs trend as programs advance, and whether recent clinical milestones translate into updated timelines. With the first patient recently dosed in the PM577a Phase 1/2 trial for Wilson disease, this earnings event offers a fresh signal on the pace of the company's in vivo liver pipeline.

Earnings Expectations

Analysts expect Prime Medicine to report a net loss of approximately $0.23 per share for the third quarter of fiscal 2026, with revenue estimates modest and variable given the company's limited collaboration income. For context, the company reported a loss of $0.24 per share in the second quarter of 2026 on revenue of roughly $1.15 million, and a wider loss of $0.28 per share in the first quarter. The prior-year third quarter produced a loss of $0.32 per share. Because EPS figures are small in absolute terms, minor variances can swing surprise percentages sharply. Key metrics to monitor include R&D expense, general and administrative costs, ending cash and investments, and any updates on cash runway or program timelines.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening, making it a practical complement to earnings-focused research.

Market Reaction and Investor Sentiment

Sentiment heading into the print has been mixed but generally constructive, supported by recent pipeline news including FDA clearance for PM647 and the first patient dosed in the PM577a trial. At the same time, Prime Medicine's shares have exhibited elevated volatility around past earnings, reflecting the market's sensitivity to clinical and financial signals. Key risk factors include a wider-than-expected quarterly loss, accelerated cash burn, or any indication that clinical timelines could slip. Conversely, clarity on enrollment progress or reaffirmed runway guidance could reinforce confidence. Because the company's revenue base is minimal, the market reaction will likely hinge more on qualitative pipeline commentary than on reported financial figures alone.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter print, investors should focus on Prime Medicine's ability to convert early clinical momentum into measurable progress. The PM577a Phase 1/2 study in Wilson disease is now underway, and updates on enrollment, initial safety observations, and dose escalation will be closely watched. Similarly, advancement of PM647 for alpha-1 antitrypsin deficiency following its regulatory clearance will be a meaningful catalyst.

Financial sustainability remains equally important. The company's cash position and burn rate will determine whether it can fund operations through key data readouts without additional financing. R&D expense trends, collaboration income, and any changes to cash runway guidance will therefore matter as much as the reported loss itself.

Finally, broader sector dynamics — including investor appetite for gene-editing names and peer data readouts — may influence sentiment. While no price predictions are being made, tracking clinical milestones, spending discipline, and balance-sheet health will be essential for understanding how the story evolves in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations